Details for Patent: 11,753,419
✉ Email this page to a colleague
Which drugs does patent 11,753,419 protect, and when does it expire?
Patent 11,753,419 protects CAPLYTA and is included in one NDA.
This patent has four patent family members in three countries.
Summary for Patent: 11,753,419
| Title: | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
| Abstract: | The invention relates to a particular substituted heterocycle fused gamma carboline, the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity. |
| Inventor(s): | Peng Li, Robert E DAVIS, Kimberly Vanover |
| Assignee: | Intra Cellular Therapies Inc |
| Application Number: | US17/757,212 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,753,419 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 11,753,419
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-002 | Apr 22, 2022 | RX | Yes | No | 11,753,419 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-003 | Apr 22, 2022 | RX | Yes | No | 11,753,419 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-001 | Dec 20, 2019 | RX | Yes | Yes | 11,753,419 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,753,419
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 4072554 | ⤷ Start Trial | |||
| Japan | 2022550635 | ⤷ Start Trial | |||
| Japan | 7261942 | ⤷ Start Trial | |||
| World Intellectual Property Organization (WIPO) | 2021119334 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
